Relationships between plasma levels of catecholamines and neuropeptides and the survival time in patients with congestive heart failure

1994 ◽  
Vol 235 (6) ◽  
pp. 595-601 ◽  
Author(s):  
S. VALDEMARSSON ◽  
A. BERGDAHL ◽  
L. EDVINSSON
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Survival Time ◽  
Plasma Levels

scholarly journals Effectiveness and Safety of Peritoneal Dialysis Treatment in Patients with Refractory Congestive Heart Failure due to Chronic Cardiorenal Syndrome

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Qiuyuan Shao ◽  
Yangyang Xia ◽  
Min Zhao ◽  
Jing Liu ◽  
Qingyan Zhang ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Peritoneal Dialysis ◽  
Survival Time ◽  
Heart Function ◽  
Cardiorenal Syndrome ◽  
Term Survival ◽  
Group A ◽  
Group B

Aims. To evaluate the effectiveness and safety of peritoneal dialysis (PD) in treating refractory congestive heart failure (RCHF) with cardiorenal syndrome (CRS).Methods. A total of 36 patients with RCHF were divided into type 2 CRS group (group A) and non-type 2 CRS group (group B) according to the patients’ clinical presentations and the ratio of serum urea to creatinine and urinary analyses in this prospective study. All patients were followed up till death or discontinuation of PD. Data were collected for analysis, including patient survival time on PD, technique failure, changes of heart function, and complications associated with PD treatment and hospitalization.Results. There were 27 deaths and 9 patients quitting PD program after a follow-up for 73 months with an average PD time of22.8±18.2months. A significant longer PD time was found in group B as compared with that in group A (29.0±19.4versus13.1±10.6months,p=0.003). Kaplan–Meier curves showed a higher survival probability in group B than that in group A (p<0.001). Multivariate regression demonstrated that type 2 CRS was an independent risk factor for short survival time on PD. The benefit of PD on the improvement of survival and LVEF was limited to group B patients, but absent from group A patients. The impairment of exercise tolerance indicated by NYHA classification was markedly improved by PD for both groups. The technique survival was high, and the hospital readmission was evidently decreased for both group A and group B patients.Conclusions. Our data suggest that PD is a safe and feasible palliative treatment for RCHF with type 2 CRS, though the long-term survival could not be expected for patients with the type 2 CRS. Registration ID Number isChiCTR1800015910.

Increased F2 isoprostane plasma levels in patients with congestive heart failure are correlated with antioxidant status and disease severity

2004 ◽  
Vol 10 (4) ◽  
pp. 334-338 ◽  
Author(s):  
M Cristina Polidori ◽  
Domenico Praticó ◽  
Ketty Savino ◽  
Joshua Rokach ◽  
Wilhelm Stahl ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Disease Severity ◽  
Plasma Levels ◽  
Antioxidant Status

scholarly journals Association between Survival Time and Changes in NT-proBNP in Cats Treated for Congestive Heart Failure

2017 ◽  
Vol 31 (3) ◽  
pp. 678-684 ◽  
Author(s):  
K.V. Pierce ◽  
J.E. Rush ◽  
L.M. Freeman ◽  
S.M. Cunningham ◽  
V.K. Yang
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Survival Time

Theophylline Toxicity—A Consequence of Congestive Heart Failure

1983 ◽  
Vol 17 (1) ◽  
pp. 59-60 ◽  
Author(s):  
Donald F. LeGatt
Keyword(s):  
Heart Failure ◽  
Elderly Patient ◽  
Congestive Heart Failure ◽  
Plasma Levels ◽  
Plasma Concentrations ◽  
Great Variability ◽  
Careful Monitoring ◽  
A Value ◽  
Oral Doses

A case is reported of an elderly patient with congestive heart failure (CHF), who was treated with juvenile oral doses of theophylline (Theo-Dur). The patient experienced toxic symptoms, and plasma concentrations were determined. A value of 60.6 μg/ml was reported and the theophylline administration was subsequently discontinued. Plasma concentrations and toxicity of theophylline are unpredictable in patients with CHF because of the great variability in clearance. This case demonstrates the necessity for careful monitoring of theophylline plasma levels in CHF patients.

Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term inotropic support

2006 ◽  
Vol 110 (4) ◽  
pp. 483-489 ◽  
Author(s):  
Michel White ◽  
Anique Ducharme ◽  
Reda Ibrahim ◽  
Lucette Whittom ◽  
Joel Lavoie ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Heart Failure ◽  
Congestive Heart Failure ◽  
Systemic Inflammation ◽  
Plasma Levels ◽  
Inotropic Support ◽  
Left Ventricular Ejection ◽  
Short Term ◽  
Hs Crp ◽  
And Oxidative Stress

In the present study, we evaluated circulating pro-inflammatory mediators and markers of oxidative stress in patients with decompensated CHF (congestive heart failure) and assessed whether clinical recompensation by short-term inotropic therapy influences these parameters. Patients with worsening CHF (n=29, aged 61.9±2.7 years), NYHA (New York Heart Association) class III–IV, and left ventricular ejection fraction of 23.7±1.8% were studied. Controls comprised age-matched healthy volunteers (n=15; 54.1±3.2 years). Plasma levels of cytokines [IL (interleukin)-6 and IL-18], chemokines [MCP-1 (monocyte chemotactic protein-1)], adhesion molecules [sICAM (soluble intercellular adhesion molecule), sE-selectin (soluble E-selectin)], systemic markers of oxidation [TBARS (thiobarbituric acid-reactive substances), 8-isoprostaglandin F2α and nitrotyrosine] and hs-CRP (high-sensitivity C-reactive protein) were measured by ELISA and colorimetric assays at admission and 30 days following 72-h milrinone (n=15) or dobutamine (n=14) infusion. Plasma IL-6, IL-18, sICAM, E-selectin, hs-CRP and oxidative markers were significantly higher in patients on admission before inotropic treatment compared with controls (P<0.05). Short-term inotropic support improved clinical status as assessed by NYHA classification and by the 6-min walk test and significantly decreased plasma levels of IL-6, IL-18, sICAM, hs-CRP and markers of oxidation (P<0.05) at 30 days. The effects of milrinone and dobutamine were similar. In conclusion, our results demonstrate that patients with decompensated CHF have marked systemic inflammation and increased production of oxygen free radicals. Short-term inotropic support improves functional status and reduces indices of inflammation and oxidative stress in patients with decompensated CHF.

Plasma Levels of Adrenomedullin in Patients with Acute Myocardial Infarction

1998 ◽  
Vol 94 (2) ◽  
pp. 135-139 ◽  
Author(s):  
Yuji Yoshitomi ◽  
Toshio Nishikimi ◽  
Shunichi Kojima ◽  
Morio Kuramochi ◽  
Shuichi Takishita ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Acute Myocardial Infarction ◽  
Congestive Heart Failure ◽  
Atrial Natriuretic Peptide ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Right Atrium ◽  
Plasma Levels ◽  
The Right

1. Adrenomedullin, a newly identified vasorelaxant peptide, participates in the regulation of the cardiovascular system. To investigate the pathophysiological significance of adrenomedullin in patients with acute myocardial infarction, we measured plasma levels of adrenomedullin. 2. Cardiac catheterization was performed on admission, after 1 day, and after 4 weeks in 36 patients with acute myocardial infarction. We measured plasma levels of adrenomedullin, atrial natriuretic peptide and brain natriuretic peptide in the right atrium, pulmonary artery and aorta. 3. Plasma levels of adrenomedullin in the right atrium (mean ± SEM) were significantly increased on admission (4.2 ± 2.6 h) in patients with acute myocardial infarction (10.6 ± 1.0 pmol/l) compared with controls (5.2 ± 0.3 pmol/l, P < 0.01). In addition, plasma levels of adrenomedullin were further elevated in patients with congestive heart failure (12.3 ± 1.4 pmol/l) compared with patients without congestive heart failure (7.8 ± 0.6 pmol/l, P < 0.01). In patients with congestive heart failure, plasma adrenomedullin on admission significantly correlated with atrial natriuretic peptide and brain natriuretic peptide. 4. These results suggest that plasma adrenomedullin increases in the early phase of acute myocardial infarction and that volume expansion may be one of the additional stimuli for the release of adrenomedullin in patients with acute myocardial infarction complicated by congestive heart failure.

Plasma levels of endothelin-1 at rest and after exercise in patients with moderate congestive heart failure

1995 ◽  
Vol 51 (3) ◽  
pp. 267-272 ◽  
Author(s):  
Pascal de Groote ◽  
Alain Millaire ◽  
André Racadot ◽  
Eric Decoulx ◽  
Gérard Ducloux
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Plasma Levels ◽  
Endothelin 1
Sign in / Sign up

Export Citation Format

Share Document